When R&D Survives, What Pays for It?
Once the R&D tax shock reaches a company’s cash account, research spending is only one possible adjustment. This chapter treats the corporate budget as a connected system and asks what the Stanford study finds when firms protect R&D by changing capital expenditures or shareholder payouts. It also separates what the data observe—financial lines and firm-level innovation measures—from what remains hidden inside a portfolio of projects. That distinction is necessary to decide whether an unchanged R&D total means “no cost” or simply “the cost appeared somewhere else.”
A firm does not fund each objective from a separate, sealed account. Cash can support researchers, equipment, acquisitions, debt service, dividends, share repurchases, or a reserve against future uncertainty. Each use has a different adjustment cost and sends a different signal to investors. When a delayed deduction increases the cash required for R&D, management must decide which margin can move without damaging the firm’s longer-term plan or creating a new financing problem.
The corporate budget has several adjustment margins
The study finds that unconstrained firms largely sustain their R&D spending after the capitalization rule raises cash taxes. That observation is easy to misread. It does not mean the rule had no economic effect on those firms. It means that R&D appears to be protected while another use of cash absorbs some of the pressure.
Share repurchases are one such margin. They are a discretionary form of payout: a company can change the amount of stock it buys without formally changing a recurring dividend commitment. In the study’s full sample, affected December fiscal-year-end firms reduce repurchases by 1.4% of assets relative to the comparison group. The treated firms’ pre-period mean repurchases are 3.4% of assets, so the estimate represents a 41.2% reduction relative to that mean.
The denominators tell two different stories. Scaling by assets places the change beside other corporate investment measures and allows firms of different sizes to be compared. Scaling by average repurchases shows how large the change is within the payout program. Neither denominator means that 1.4% of every dollar of sales disappeared, or that the company stopped returning all capital to shareholders. The evidence concerns the amount of repurchases in the measured period.
Capital expenditures also fall. The study measures capital investment as capital expenditures divided by prior-year property, plant, and equipment. The estimated coefficient is -0.074, or a 7.4% reduction on that base. The treated firms’ mean capital-investment measure is 0.296, so the reduction is about 25% of that mean. This is a substantial movement in another investment category, even when the R&D line is protected.
The two adjustments are not identical. Repurchases distribute cash to shareholders; capital expenditures purchase or build productive assets. Reducing either can influence future capacity, but the timing and reversibility differ. A repurchase can often be scaled back in the current period. A postponed factory upgrade, laboratory expansion, or equipment purchase may affect production or research capacity for longer. The study does not convert these changes into one common measure of lost value, so the right conclusion is about allocation, not a ranking of which margin is socially preferable.
The results appear in subsamples of firms considered unconstrained, including larger, older, and positive-cash-flow groups. This pattern fits the financing mechanism. A firm with more slack can preserve a strategically important research program and use a more flexible payout or investment decision as the buffer.